Climb Bio (CLYM) News
NASDAQ: CLYMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
9.19-0.09 (-0.97%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CLYM news summary
We found 9 recent headlines mentioning Climb Bio (CLYM): 0 in the past week and 7 in the past 30 days, most often from GlobeNewswire, Investing.com, Nasdaq. For price context, CLYM is down 0.97% at $9.19. The most recent story, "Wedbush keeps Climb Bio on Best Ideas List, raises price target", was published by Investing.com on Nov 6, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Climb Bio headlines
- Wedbush keeps Climb Bio on Best Ideas List, raises price targetInvesting.com
- Climb Bio Non-GAAP EPS of -$0.18 beats by $0.02Seeking Alpha
- Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business UpdatesCLYM116 Phase 1 data in healthy volunteers showed sustained >90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks after a single dose, supporting every-12-week dosingGlobeNewswire
- Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and ExpositionWELLESLEY HILLS, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases,…GlobeNewswire
- Climb Bio, Inc. Announces Initial PrisMN Phase 2 Data for Budoprutug in Primary Membranous NephropathyClimb Bio, Inc. announced initial PrisMN Phase 2 data for budoprutug, its anti-CD19 monoclonal antibody, in primary membranous nephropathy (“pMN”). PrisMN is an ongoing Phase 2…Nasdaq
- Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study…GlobeNewswire
- Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026>90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing intervalGlobeNewswire
- Why is Climb Bio stock surging today?Investing.com
- Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?Here is how Climb Bio, Inc. (CLYM) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.NasdaqCLYM, HALO